In this episode Lisa is joined via zoom by Dr Andrew Last and Dr Georgia Harris. Lisa, Andrew and Georgia discuss hypofractionation and the evidence and benefits of its use in early breast cancer, the impact of COVID on prescribing patterns, ultra-hypofractionation and the results of the FAST-Forward trial, as well as providing some tips to help get you started in implementing hypofractionation at your treatment centre.

This podcast introduces some concepts and terminology you may not be familiar with.
Before you listen, you may like to complete the eviQ Education hypofractionation rapid learning module and view the terminology table.

 

 

Transcript

Resources

Want to learn more about hypofractionated radiation therapy? Check out the following links and spread the word.

eviQ protocol - https://www.eviq.org.au/radiation-oncology/breast/3650-breast-invasive-cancer-adjuvant-whole-breast

Cancer Australia - Update guidance for the management of early breast cancer (September 2020).

American Society for Radiation Oncology (ASTRO) Guidelines (2018) - Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline, American Society for Radiation Oncology (ASTRO) evidence-based guideline, 2018

FAST- Forward Trial‚Äč - Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.

 

Create your own user feedback survey